Valeria La Pietra

Valeria La Pietra

Auto-generated profile, based on publicly available information

Valeria La Pietra

University of Naples Federico II

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SDSimona Daniele
Simona Daniele
VPValeria La Pietra
Valeria La Pietra
RPRebecca Piccarducci
Rebecca Piccarducci
DPDeborah Pietrobono
Deborah Pietrobono
Chiara CavalliniChiara Cavallini
Chiara Cavallini
Luciana MarinelliLuciana Marinelli
Luciana Marinelli

30 September 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
mariateresa giustinianomariateresa giustiniano
mariateresa giustiniano
SDSimona Daniele
Simona Daniele
SPSveva Pelliccia
Sveva Pelliccia
VPValeria La Pietra
Valeria La Pietra
DPDeborah Pietrobono
Deborah Pietrobono
Luciana MarinelliLuciana Marinelli
Luciana Marinelli

27 November 2024 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
Pasquale PerronePasquale Perrone
Pasquale Perrone
RNRosaria Notariale
Rosaria Notariale
Gennaro LettieriGennaro Lettieri
Gennaro Lettieri
LMLuigi Mele
Luigi Mele
VPValeria La Pietra
Valeria La Pietra
CMCaterina Manna
Caterina Manna
In several physiopathological processes, phosphatidylserine (PS), normally sequestered to the inner leaflet of the plasma membrane, becomes exposed to the cell surface. In erythrocytes (RBC), PS externalization is a crucial event for the removal of aged/damaged cells but can also be associated with increased prothrombotic activity. Structurally related olive oil antioxidants, including hydroxytyrosol (HT), are able to significantly reduce the percentage of PS-exposing RBC, when cells are exposed to toxic compounds such as the heavy metal mercury (Hg). The aim of the present study was to identify the molecular mechanisms underlying the protective effect, with a focus on two different phospholipid translocases, the ATP-dependent flippase ATP11C and the calcium-dependent scramblase PLSCR1, which are responsible for PS internalization and exposure, respectively. In addition to HT, its monophenol analogue, tyrosol, and its in vivo metabolite, homovanillic alcohol, were also tested. Our investigation revealed that exposure of human intact RBC to HgCl2 induced a decrease in flippase activity and an increase in scramblase activity, and that all the selected phenols restored the control activity, regardless of their different scavenging properties. Interestingly, all phenols restored the ATP level of control cells, which were significantly reduced by HgCl2 treatment. Conversely, no variation in intracellular calcium was observed under our experimental conditions. Additionally, all phenols restored the glutathione levels, significantly reduced in the presence of HgCl2. In line with the data on the enzymatic activity, Western blotting analysis indicated changes in the membrane expression of the two enzymes, alterations prevented by antioxidant pre-treatment. Finally, molecular docking analysis suggests that the tested antioxidants may be able to directly interact with ATP11C. Our findings provide an experimental basis for the use of olive oil bioactive compounds in nutritional/nutraceutical strategies for the prevention of Hg-related toxicity, particularly in relation to the cardiovascular tissues.

29 January 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Francesco MerlinoFrancesco Merlino
Francesco Merlino
APAnnalisa Pecoraro
Annalisa Pecoraro
GLGiuseppe Longobardi
Giuseppe Longobardi
GDGreta Donati
Greta Donati
FLFrancesco Saverio Di Leva
Francesco Saverio Di Leva
VPValeria La Pietra
Valeria La Pietra

11 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
IBIvana Barravecchia
Ivana Barravecchia
EBelisabetta barresi
elisabetta barresi
CRCamilla Russo
Camilla Russo
FSFrancesca Scebba
Francesca Scebba
CCChiara De Cesari
Chiara De Cesari
Luciana MarinelliLuciana Marinelli
Luciana Marinelli
Molecule interacting with CasL 2 (MICAL2), a cytoskeleton dynamics regulator, are strongly expressed in several human cancer types, especially at the invasive front, in metastasizing cancer cells and in the neo-angiogenic vasculature. Although a plethora of data exist and stress a growing relevance of MICAL2 to human cancer, it is worth noting that only one small-molecule inhibitor, named CCG-1423 (1), is known to date. Herein, with the aim to develop novel MICAL2 inhibitors, starting from CCG-1423 (1), a small library of new compounds was synthetized and biologically evaluated on human dermal microvascular endothelial cells (HMEC-1) and on renal cell adenocarcinoma (786-O) cells. Among the novel compounds, 10 and 7 gave interesting results in terms of reduction in cell proliferation and/or motility, whereas no effects were observed in MICAL2-knocked down cells. Aside from the interesting biological activities, this work provides the first structure–activity relationships (SARs) of CCG-1423 (1), thus providing precious information for the discovery of new MICAL2 inhibitors.

18 December 2023 in Archiv der Pharmazie
Verified
Journal Article
Open access
Greta DonatiGreta Donati
Greta Donati
MVMonica Viviano
Monica Viviano
VDVincenzo Maria D'AMore
Vincenzo Maria D'AMore
ACAlessandra Cipriano
Alessandra Cipriano
IDIsidora Diakogiannaki
Isidora Diakogiannaki
LMLuciana Marinelli
Luciana Marinelli
Immunotherapy has emerged as a game‐changing approach for cancer treatment. Although monoclonal antibodies (mAbs) targeting the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD‐1/PD‐L1) axis have entered the market revolutionizing the treatment landscape of many cancer types, small molecules, although presenting several advantages including the possibility of oral administration and/or reduced costs, struggled to enter in clinical trials, suffering of water insolubility and/or inadequate potency compared with mAbs. Thus, the search for novel scaffolds for both the design of effective small molecules and possible synergistic strategies is an ongoing field of interest. In an attempt to find novel chemotypes, a virtual screening approach was employed, resulting in the identification of new chemical entities with a certain binding capability, the most versatile of which was the benzimidazole‐containing compound 10. Through rational design, a small library of its derivatives was synthesized and evaluated. The homogeneous time‐resolved fluorescence (HTRF) assay revealed that compound 17 shows the most potent inhibitory activity (IC50) in the submicromolar range and notably, differently from the major part of PD‐L1 inhibitors, exhibits satisfactory water solubility properties. These findings highlight the potential of benzimidazole‐based compounds as novel promising candidates for PD‐L1 inhibition.